Labetalol and Esmolol: Vital Signs and Post Operative Pain Management
Completed
Cedars-Sinai Medical Center
Phase 4
2009-09-03
This study proposes to investigate the effects of labetalol or esmolol on managing the vital
signs (like blood pressure and heart rate) during surgery, on pain management, and on the
later recovery after surgery.
It will also assess the cost-effectiveness of Labetalol and esmolol for outpatient surgery.
Esmolol Infusion During Laminectomy: Effect on Quality of Recovery
Terminated
Cedars-Sinai Medical Center
Phase 4
2011-06-01
The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly
administered during surgery to help control blood pressure and heart rate, on postoperative
pain levels and requirements for pain medication.
Esmolol for Treatment of Perioperative Tachycardia
Terminated
Baxter Healthcare Corporation
Phase 3
2010-09-01
The purpose of this study is to find out if Esmolol is a safe and effective alternative
treatment compared to standard treatment using a long acting beta blocker drug, in
controlling abnormal heart rate before, during and immediately after surgery.
Esmolol for Treatment of Perioperative Tachycardia
Terminated
Duke University
Phase 3
2010-09-01
The purpose of this study is to find out if Esmolol is a safe and effective alternative
treatment compared to standard treatment using a long acting beta blocker drug, in
controlling abnormal heart rate before, during and immediately after surgery.
Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage
Withdrawn
University of Michigan
N/A
2014-07-01
The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac
function and electrophysiology; to assess the effects of esmolol treatment on serum
adrenergic and cardiac biomarkers; to explore the safety of esmolol treatment shortly after
subarachnoid hemorrhage (SAH). Patients will be followed for a maximum of 1 month after the
index SAH. The primary outcome will be change in systolic function - ejection fraction by
Simpson's rule (baseline versus Day 7 +/- 2 after SAH).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
